| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-04-28 23:27:41 UTC |
|---|
| Updated at | 2022-04-28 23:27:41 UTC |
|---|
| NP-MRD ID | NP0078365 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Bufalin |
|---|
| Description | Bufalin belongs to the class of organic compounds known as bufanolides and derivatives. These are steroid lactones containing a pyran-2-one moiety linked to the C17 atom of a cyclopenta[a]phenanthrene derivative. Thus, bufalin is considered to be a sterol. Bufalin is found in Apis cerana, Bufo bankorensis, Bufo bufo, Bufo gargarizans, Cunninghamella blakesleana, Cunninghamella blakesleeana, Duttaphrynus melanostictus, Bryophyllum pinnatum and Phrynoidis asper. Bufalin was first documented in 2022 (PMID: 35409366). Based on a literature review a small amount of articles have been published on bufalin (PMID: 35345394) (PMID: 35241510) (PMID: 35235052) (PMID: 35153791). |
|---|
| Structure | C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=COC(=O)C=C1 InChI=1S/C24H34O4/c1-22-10-7-17(25)13-16(22)4-5-20-19(22)8-11-23(2)18(9-12-24(20,23)27)15-3-6-21(26)28-14-15/h3,6,14,16-20,25,27H,4-5,7-13H2,1-2H3/t16-,17+,18-,19+,20-,22+,23-,24+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 3,14-Dihydroxy-bufa-20,22-dienolide | ChEBI | | 3-beta,14-Dihydroxy-5-beta-bufa-20,22-dienolide | ChEBI | | 3beta,14beta-Dihydroxy-5beta-bufa-20,22-dienolide | ChEBI | | (3beta,5beta)-3,14-Dihydroxybufa-20,22-dienolide | Kegg | | 3-b,14-Dihydroxy-5-b-bufa-20,22-dienolide | Generator | | 3-Β,14-dihydroxy-5-β-bufa-20,22-dienolide | Generator | | 3b,14b-Dihydroxy-5b-bufa-20,22-dienolide | Generator | | 3Β,14β-dihydroxy-5β-bufa-20,22-dienolide | Generator | | (3b,5b)-3,14-Dihydroxybufa-20,22-dienolide | Generator | | (3Β,5β)-3,14-dihydroxybufa-20,22-dienolide | Generator | | Bufalin, (3alpha,5beta)-isomer | MeSH |
|
|---|
| Chemical Formula | C24H34O4 |
|---|
| Average Mass | 386.5320 Da |
|---|
| Monoisotopic Mass | 386.24571 Da |
|---|
| IUPAC Name | 5-[(1S,2S,5S,7R,10R,11S,14S,15R)-5,11-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-2H-pyran-2-one |
|---|
| Traditional Name | 5-[(1S,2S,5S,7R,10R,11S,14S,15R)-5,11-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pyran-2-one |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=COC(=O)C=C1 |
|---|
| InChI Identifier | InChI=1S/C24H34O4/c1-22-10-7-17(25)13-16(22)4-5-20-19(22)8-11-23(2)18(9-12-24(20,23)27)15-3-6-21(26)28-14-15/h3,6,14,16-20,25,27H,4-5,7-13H2,1-2H3/t16-,17+,18-,19+,20-,22+,23-,24+/m1/s1 |
|---|
| InChI Key | QEEBRPGZBVVINN-BMPKRDENSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as bufanolides and derivatives. These are steroid lactones containing a pyran-2-one moiety linked to the C17 atom of a cyclopenta[a]phenanthrene derivative. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Steroid lactones |
|---|
| Direct Parent | Bufanolides and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Bufanolide-skeleton
- 3-hydroxysteroid
- 14-hydroxysteroid
- Hydroxysteroid
- 3-beta-hydroxysteroid
- Pyranone
- Pyran
- Tertiary alcohol
- Heteroaromatic compound
- Cyclic alcohol
- Secondary alcohol
- Lactone
- Oxacycle
- Organoheterocyclic compound
- Organic oxygen compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Alcohol
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Sampath V, Horesh N, Sasi B, Zannadeh H, Pogodin I, Singh SV, Deutsch J, Lichtstein D: Synthesis and Biological Evaluation of Novel Bufalin Derivatives. Int J Mol Sci. 2022 Apr 4;23(7):4007. doi: 10.3390/ijms23074007. [PubMed:35409366 ]
- Jiang HY, Zheng HM, Xia C, Li X, Wang G, Zhao T, Cui XN, Wang RY, Liu Y: The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma. Onco Targets Ther. 2022 Mar 22;15:291-298. doi: 10.2147/OTT.S333233. eCollection 2022. [PubMed:35345394 ]
- Kuo JY, Liao CL, Ma YS, Kuo CL, Chen JC, Huang YP, Huang WW, Peng SF, Chung JG: Combination Treatment of Sorafenib and Bufalin Induces Apoptosis in NCI-H292 Human Lung Cancer Cells In Vitro. In Vivo. 2022 Mar-Apr;36(2):582-595. doi: 10.21873/invivo.12741. [PubMed:35241510 ]
- Kreutzer FP, Meinecke A, Mitzka S, Hunkler HJ, Hobuss L, Abbas N, Geffers R, Weusthoff J, Xiao K, Jonigk DD, Fiedler J, Thum T: Development and characterization of anti-fibrotic natural compound similars with improved effectivity. Basic Res Cardiol. 2022 Mar 2;117(1):9. doi: 10.1007/s00395-022-00919-6. [PubMed:35235052 ]
- Yu CC, Li Y, Cheng ZJ, Wang X, Mao W, Zhang YW: Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions. Front Pharmacol. 2022 Jan 27;13:818179. doi: 10.3389/fphar.2022.818179. eCollection 2022. [PubMed:35153791 ]
|
|---|